Pyrazole-derived TRPC3 antagonist ameliorates synaptic dysfunctions and memory deficits in Alzheimer’s disease models
dyshomeostasis in AD. Our work identifies TRPC3 as a potential therapeutic target for treating or preventing synaptic dysfunction of AD.
Authors
- H J Zhang
- S Zhang
- Dongyi Ding
- Francesca‐Fang Liao (ORCID: https://orcid.org/0000-0001-5144-3600)
- Vijay K. Boda (ORCID: https://orcid.org/0000-0001-7299-2369)
- Tyler C. Ortyl (ORCID: https://orcid.org/0000-0002-7479-4005)
- Zhengjun Wang
- Ling Chen (ORCID: https://orcid.org/0000-0002-6468-5729)
- Xingyong Chen (ORCID: https://orcid.org/0000-0001-7364-5414)
- Ilya Bezprozvanny (ORCID: https://orcid.org/0000-0001-7006-6951)
- Zhongzhi Wu
- Geng Lin
- Peter T. Nelson
- Ryan Rager-Aguiar
- Jiaxing Wang (ORCID: https://orcid.org/0000-0002-3202-2402)
- Fu-Ming Zhou
- Wei Li
Institutions
- Fujian Medical University (CN)
- University of Kentucky (US)
- University of Tennessee Health Science Center (US)
- Peter the Great St. Petersburg Polytechnic University (RU)
- Fujian Provincial Hospital (CN)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Molecular Psychiatry
- Published
- 2026-04-11
- DOI
- https://doi.org/10.1038/s41380-026-03592-6
- Primary Topic
- Ion Channels and Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health